JAK1, Janus kinase 1, 3716

N. diseases: 239; N. variants: 41
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. 31719581 2019
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE We hypothesized that selective inhibition of JAK1/2 by ruxolitinib could induce autophagy and limit drug efficacy in myeloproliferative neoplasms (MPN). 31286322 2019
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. 31289316 2019
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolitinib. 30571852 2019
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE Inhibition of Janus-kinase 1/2 (JAK1/2) is a mainstay to treat myeloproliferative neoplasms (MPN). 29907599 2018
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 GeneticVariation group BEFREE The discovery of the activating Janus kinase (JAK)2<sup>V617F</sup> mutation in 2005 in most patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in the gene encoding calreticulin (CALR) in 2013, thus providing additional mechanistic explanations for the universal activation of JAK-signal transducer and activator of transcription (JAK-STAT) observed in these conditions, and the success of the JAK1/2 inhibitor ruxolitinib, which first received regulatory approval in 2011. 29277359 2018
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE Momelotinib is a potent and selective small-molecule inhibitor of JAK1/2 that is under investigation for the treatment of myeloproliferative neoplasms. 29024542 2018
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 AlteredExpression group BEFREE Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation. 29515770 2018
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. 29056075 2018
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 AlteredExpression group BEFREE Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. 27677740 2017
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE There has been a major revolution in the management of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly and symptomatic burden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib. 28028027 2017
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL). 26443624 2015
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 GeneticVariation group BEFREE Abstract Considering the recent impact of tyrosine kinase inhibitors in the treatment of myeloproliferative disorders carrying a recurrent JAK2 mutation not identified in multiple myeloma (MM), this study aimed to search for mutations in kinase and pseudokinase domains of the JAK1 gene in an attempt to define any critical and recurring change that can be used as a therapeutic target. 23885837 2014
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN). 22875628 2013
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease
0.100 Biomarker group BEFREE Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. 20130243 2010